presented by mario sznol at 2014 asco annual meeting
DESCRIPTION
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) . Presented By Mario Sznol at 2014 ASCO Annual Meeting. Disclosures. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Presented By Mario Sznol at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022081502/568160dc550346895dd00d49/html5/thumbnails/1.jpg)
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in<br /> advanced melanoma (MEL)
Presented By Mario Sznol at 2014 ASCO Annual Meeting
![Page 2: Presented By Mario Sznol at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022081502/568160dc550346895dd00d49/html5/thumbnails/2.jpg)
Disclosures
Presented By Mario Sznol at 2014 ASCO Annual Meeting
![Page 3: Presented By Mario Sznol at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022081502/568160dc550346895dd00d49/html5/thumbnails/3.jpg)
Ipilimumab and Nivolumab Clinical Experience in Patients with Advanced Melanoma
Presented By Mario Sznol at 2014 ASCO Annual Meeting
![Page 4: Presented By Mario Sznol at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022081502/568160dc550346895dd00d49/html5/thumbnails/4.jpg)
Objectives
Presented By Mario Sznol at 2014 ASCO Annual Meeting
![Page 5: Presented By Mario Sznol at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022081502/568160dc550346895dd00d49/html5/thumbnails/5.jpg)
CA209-004 Phase I Study: Dose Cohorts
Presented By Mario Sznol at 2014 ASCO Annual Meeting
![Page 6: Presented By Mario Sznol at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022081502/568160dc550346895dd00d49/html5/thumbnails/6.jpg)
Patient Demographics
Presented By Mario Sznol at 2014 ASCO Annual Meeting
![Page 7: Presented By Mario Sznol at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022081502/568160dc550346895dd00d49/html5/thumbnails/7.jpg)
Activity Summary: Concurrent and Sequenced Cohorts from 004
Presented By Mario Sznol at 2014 ASCO Annual Meeting
![Page 8: Presented By Mario Sznol at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022081502/568160dc550346895dd00d49/html5/thumbnails/8.jpg)
Response in Target Lesions
Presented By Mario Sznol at 2014 ASCO Annual Meeting
![Page 9: Presented By Mario Sznol at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022081502/568160dc550346895dd00d49/html5/thumbnails/9.jpg)
Slide 9
Presented By Mario Sznol at 2014 ASCO Annual Meeting
![Page 10: Presented By Mario Sznol at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022081502/568160dc550346895dd00d49/html5/thumbnails/10.jpg)
Characteristics of Response
Presented By Mario Sznol at 2014 ASCO Annual Meeting
![Page 11: Presented By Mario Sznol at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022081502/568160dc550346895dd00d49/html5/thumbnails/11.jpg)
Safety Overview
Presented By Mario Sznol at 2014 ASCO Annual Meeting
![Page 12: Presented By Mario Sznol at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022081502/568160dc550346895dd00d49/html5/thumbnails/12.jpg)
ORR by BRAF Status for Concurrent Cohorts
Presented By Mario Sznol at 2014 ASCO Annual Meeting
![Page 13: Presented By Mario Sznol at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022081502/568160dc550346895dd00d49/html5/thumbnails/13.jpg)
ORR by PD-L1 Status (5% cutoff)
Presented By Mario Sznol at 2014 ASCO Annual Meeting
![Page 14: Presented By Mario Sznol at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022081502/568160dc550346895dd00d49/html5/thumbnails/14.jpg)
ORR by Ipilimumab Exposure at Time <br />of Nivolumab Treatment
Presented By Mario Sznol at 2014 ASCO Annual Meeting
![Page 15: Presented By Mario Sznol at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022081502/568160dc550346895dd00d49/html5/thumbnails/15.jpg)
Overall Survival for Concurrent <br />Therapy by Dose Cohort
Presented By Mario Sznol at 2014 ASCO Annual Meeting
![Page 16: Presented By Mario Sznol at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022081502/568160dc550346895dd00d49/html5/thumbnails/16.jpg)
Survival Endpoints for Concurrent and Sequential Therapy by Dose Cohort
Presented By Mario Sznol at 2014 ASCO Annual Meeting
![Page 17: Presented By Mario Sznol at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022081502/568160dc550346895dd00d49/html5/thumbnails/17.jpg)
Conclusions
Presented By Mario Sznol at 2014 ASCO Annual Meeting
![Page 18: Presented By Mario Sznol at 2014 ASCO Annual Meeting](https://reader036.vdocument.in/reader036/viewer/2022081502/568160dc550346895dd00d49/html5/thumbnails/18.jpg)
Acknowledgments
Presented By Mario Sznol at 2014 ASCO Annual Meeting